• Can changes in EEG improve neuropathic pain treatments - read Oct newsletter.
  • Nine posters ready to reveal at the SfN virtual conference 8-11 Nov, booth 1818.
  • Joined-up preclinical and clinical trials to advance psilocybin drug development
  • Transpharmation joins HaPpY team to help break the vicious cycle of chronic pain & mood disorders, see News for details
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • New state-of-the-art premises at Discovery Park, Kent
 

Partnerships

These are some of the businesses we collaborate or team up with...

Clerkenwell Health

Clerkenwell HealthClerkenwell Health is an innovative, UK-based mental health start-up building a platform to accelerate patients’ access to a range of psychedelic-assisted therapies over the coming years. Clerkenwell is focused on helping its clients generate the clinical data required to mainstream these exciting treatment methodologies with doctors and regulators alike.

The team is led by CEO Tom McDonald, a former Accenture pharmaceutical specialist with a focus on patient-centric care and CSO Dr Henry Fisher, a chemist and drug policy expert. Patient therapy is led by Dr Sara Tai, a clinical psychologist, a Senior Lecturer in Clinical Psychology at the University of Manchester and an expert in psychotherapy in clinical trials of psychedelic medicine. www.clerkenwellhealth.com

“This partnership offers up a rare opportunity to deliver some truly joined up thinking in terms of preclinical and clinical research. Given the potential that psilocybin and related psychedelic compounds present as clinical tools across a range of indications, this is a hugely exciting development for advancing the clinical development process. This partnership will greatly assist companies in this space with accelerating their goal of market approval.” - Clerkenwell Health CSO Henry Fisher

“It’s fantastic to formalise our relationship with such a well-established preclinical testing specialist. Transpharmation’s expertise in the neuroscience and psychedelics field perfectly complements the work we are doing at Clerkenwell and ensures that we can provide our clients with the full suite of CRO services from early stage regulatory advisory through to trial design and delivery at any stage of the drug development life cycle.” - Clerkenwell CEO Tom McDonald

“As a UK-based and scientist-led company, we are proud of our part in keeping the UK at the forefront of this important research area. Importantly, our clients around the world are choosing to work with us and UK companies for the strength of science; our partnership with Clerkenwell itself was enabled by a multi-million dollar international contract. The future for UK bioscience, with benefits to human health and drug discovery, is extremely strong.” - Mark Duxon, CEO Transpharmation


HaPpY

varsity bio“Comorbidity of chronic pain and mood disorders: breaking the vicious cycle” - this is the aim of the HaPpY grant from Innovative Training Networks, who have assembled a world-class team of behavioural neuroscientists, electrophysiologists, molecular biologists, neuropharmacologists and clinicians specialising in pain and/or mood disorders from academic research labs and hospitals along with experts from the non-academic sector. Transpharmation is delighted to have been invited to join as well-known experts in this therapeutic area and we look forward to delivering training to young scientists.

Website: https://happyejd.com/
LinkedIn: https://www.linkedin.com/company/happy-itn-network
Twitter: https://twitter.com/HaPpYejd2021


InterVivo Solutions

intervinoInterVivo is a Canadian-based preclinical contract research organization focused on Central Nervous System indications. In 2017, Transpharmation and InterVivo Solutions announced a strategic joint venture to co-market and co-develop their translational research services, combining their pre- existing Global client bases to deliver ‘best in class’ translational Drug Discovery support.

 


Blue Oak Pharmaceuticals

intervinoBlue Oak drug hunters are experts in the systems neurobiology of brain disorders, medical chemistry and informatics. Their leading productivity integrates a global research team with cutting edge technologies in behavioural profiling, synthetic chemistry and brain imaging.

 


University of Hertfordshire

uni hertfordshireThe University of Hertfordshire and Transpharmation undertake collaborative research projects and co-fund / co-supervise PhD studentships, combining the expertise of research scientists from both organisations to further capabilities and develop new assays.

 


Varsity BioLogistics

varsity bioGuaranteed biological shipping. Temperature sensitive, time critical biological sample shipment within the UK and globally.

 

 


Metris

varsity bioMetris provide Innovative solutions, instruments and software for animal behaviour research.

 

 


BonePain II

bio painBonePain II is a European training network promoting innovation and education within bone pain research. The BonePain II network encompasses 8 academic groups and 4 industries all committed to creating an outstanding training programme for early stages researchers to elucidate the mechanisms of bone pain and develop new medicines.

 


Direct Pathways

directpath

Direct Pathways is a consultancy firm who support businesses to work more efficiently and focus on the building blocks for growth and increased profitability.  We have worked with them to improve business performance by tightening our core structures and empowering our people to be more effective.

 


 

Start a Conversation

preclinical +44 (0)203 633 2807

clinical trials +353 (0)1896 42 60

clinical research +48 515 244 120

EEG contact@transpharmation.co.uk


Copyright ©2021 Transpharmation Ltd. Website created by Identity Ipswich Web Design